Background: The effect of risperidone treatment in patients with schizophrenia varies according to the dopamine receptor genes. This study aimed to evaluate the relationship between genes of the dopamine receptors (D1, D2, and D3) and the effect of risperidone treatment. Methods: Three electronic databases (PubMed, Embase, and Cochrane Library) were searched for relevant cohort or case-control studies published before 9 May 2018. A systematic review and meta-analysis was performed for qualitative and quantitative assessment of the relationship between the dopamine receptors D1, D2, and D3 (DRD1, 2, and 3) and the effect of risperidone treatment. The summary odds ratio (OR) and weighted mean difference (WMD) in a random-effects model were used to measure these relationships. Results: Twelve studies involving 24 SNPs were included. DRD2 (Ser311Cys, rs1801028 Ser/Ser) significantly lowered the improvement rate (determined by the PANSS score) unlike Ser/Cys (WMD: −11.58, 95% CI: −17.35 to −5.18). For Asian patients, A241G (rs1799978) AA carriers showed greater improvement after risperidone therapy (P < 0.05). The polymorphisms of 141C Ins/Del (rs1799732), T939C (rs6275), rs6277, and TaqID (rs1800498) may also influence the treatment effect. TaqIA (rs1800497) and TaqIB (rs17294542) were not associated with the rate of response to risperidone. DRD3 was not associated with an improvement in the PANSS total score; however, Ser9Gly might be related to a change in negative symptoms. No significant effect of DRD1 (rs5326, rs4867798, rs4532, and rs11749676) was found. Conclusions: Our result supported the hypothesis that DRD2 affected risperidone treatment. DRD1 had no significant effect on the response to risperidone, whereas DRD3 might be associated with an improvement in negative symptoms. Larger observational studies are warranted to verify these findings and identify other genetic factors involved.
| INTRODUCTION
Schizophrenia, a complex and severe psychiatric disease, is a multifactorial psychiatric disorder that involves both environmental and genetic factors, with 1% of the world's population thought to have the disease. 1, 2 Patients with schizophrenia need long-term treatment to maintain social function and prevent symptom relapse. 3 However, the large interindividual variability in the response to antipsychotics remains a challenge in treatment of schizophrenia. 4 Understanding this individual variability in treatment response is a critical first step towards drugs with improved efficacy. Currently, the benzisoxazole derivative risperidone is widely used for the treatment of schizophrenia and related psychotic disorders, 5 and genetic polymorphisms have been reported to have an important role in the interindividual differences in the response to treatment. 6 Several polymorphisms that affect efficacy have been described in atypical antipsychotics; however, these associations were not confirmed owing to the small number of subjects included in the relevant studies. In addition, as different antipsychotics have different capacities for combination with the D1-D5 dopamine receptors and the 5-HT receptor, the impact of the same genotypes or haplotypes on different antipsychotics may not be identical. The association between dopamine receptor genes and the effect of risperidone treatment has been explored in several studies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ; however, a consistent association between the efficacy of risperidone and genetic factors has not been established. In the present study, we therefore summarized the current pharmacogenetic literature to evaluate the correlation between dopamine receptor genes and the response to risperidone in patients with schizophrenia and performed a meta-analysis of available studies.
| MATERIALS AND METHODS

| Data sources, search strategy, and selection criteria
The present survey was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement, 2009. 19 Relevant articles that evaluated the relationships between the dopamine receptor genes (DRD1, DRD2, DRD3) and the effect of risperidone treatment were systematically searched for in the following databases: PubMed, Embase, and Cochrane Library (search range: from database inception to 9 May 2018). Our search criteria were: human studies, without language restrictions, and publication status (published, in press, or in progress); the core search included the following terms: (risperidone OR risperidal) AND (polymorphisms OR pharmacogenetics). If a specific dataset had been published more than once, the most recent and complete publication was used. Furthermore, the reference lists of the identified reports, reviews, and other relevant publications were examined to find additional pertinent studies. The literature search and study selection were undertaken by two authors independently and any inconsistencies were resolved through group discussion. A study was eligible for inclusion in our analysis after fulfilment of the following criteria: (a) the study had an observational design (cohort or case-control); (b) the study included patients with schizophrenia that received risperidone; (c) the study investigated the correlation between dopamine receptors D1, D2, or D3 and the treatment effects of risperidone (response to risperidone, positive and negative syndrome scale [PANSS] score, brief psychiatric rating scale [BPRS] , and Clinical Global Impression-Global Improvement scale [CGI-I]).
| Data collection and quality assessment
All data from the included studies were abstracted by two authors independently. After importing the items into Excel, two authors independently extracted the data, placed them into the files, and then checked the imported data. Any disagreement between the two authors was resolved through group discussion. In addition, the data collected from each included study comprised the following parameters: first author, publication year, country, sample size, number of male and female subjects, mean age, treatment durations, risperidone doses, and genotypes. Furthermore, in order to evaluate the methodological quality, the Newcastle-Ottawa Scale (NOS) was applied to assess the quality of the observational studies included in the metaanalysis. 20 The NOS was based on the following three subscales: selection (four items), comparability (one item), and outcome (three items). A "star system" (range 0-9) has been developed for assessment. Simultaneously, data extraction and quality assessment were performed independently by two authors. Finally, the required information was examined and confirmed independently by a third author.
| Statistical analysis
Meta-analyses were performed for the SNPs with multiple studies available to merge; otherwise, we conducted a systematic review. For the meta-analysis, the correlation of the DRD1-3 and the treatment effect of risperidone was examined based on crude data for dichotomy variable and the mean, standard deviation, and sample size in each group for each individual study. To compare the different categories with the control category for each genotype of DRD1-3, a random-effects model was used to assess the pooled effect estimate. 21, 22 Furthermore, the odds ratio (OR) and weighted mean difference (WMD) with corresponding 95% confidence intervals (CIs) were calculated to evaluate these associations. The heterogeneity among studies was investigated by using the Q statistic; P values of <0.10 were considered to indicate significant heterogeneity. All reported P values were two-sided, with P < 0.05 regarded as statistically significant for the included studies. Statistical analyses were computed by using Review Manager (RevMan. Version 5.3; Copenhagen, Denmark: the Nordic Cochrane Centre, the Cochrane Collaboration, 2015).
| RESULTS
The initial electronic search identified 638 articles (287 from Pubmed, 52 from Cochrane Library, and 299 from Embase), of which 249 duplicates were excluded. Subsequently, another 304 studies were excluded after an initial review of the titles and abstracts. The full text of the remaining 85 included articles was retrieved, which encompassed 12 studies that satisfied the inclusion criteria ( Figure 1 ). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] A manual search of the reference lists contained within these studies did not yield any new eligible studies. The characteristics of the included studies are summarized in Tables 1-3 . The number of subjects included in each study was between 60 and 690. The quality of the studies was then evaluated by the NOS scale and summarized in Table 1 .
| DRD1
Two articles investigating fives SNPs reported the association of DRD1 polymorphisms with the effect of risperidone treatment. Huo et al 7 investigated the impact of rs5326, rs4867798, and rs4532 on risperidone treatment efficacy in 185 Chinese patients with schizophrenia. Patient data from different subcentres (Shanghai and Henan) were reported separately. They defined a cut-off of more than a 50% reduction of PANSS total score as the response criterion. No significant differences in genotypes or allele frequencies were observed between responders and nonresponders in samples from either Shanghai or Henan (P > 0.05). Huo compared the percentage reduction in PANSS scores among different genotype groups to confirm the results, and found no significant association. We combined the results of these two subcentres and the WMD of percentage reduction in PANSS total score for different genotypes of the three SNPs are shown in Figure 2A -C. Han et al 8 selected 690 schizophrenic patients and studied the influence of rs11746641 and rs11749676 on the therapeutic effect of risperidone, but neither were associated with changes in the treatment efficacy of risperidone (P = 0.060 and P = 0.086, respectively). It should be mentioned that after calculation of the WMD among the genotypes of rs11746641 T>G, we noted that unlike the TT group, the GG group experienced a slightly greater improvement in PANSS total score (WMD: 4.92, 95% CI: 1.21-8.63, Figure 2D ).
| DRD2
Within the DRD2 genotype, there were nine SNPs polymorphisms of interest. In the meta-analysis of the relationship of Taq1A (rs1800497) to risperidone treatment response, 552 patients were included in three studies. [9] [10] [11] There was no significant difference between each genotype in response to risperidone (A1A1 vs A1A2: OR: 1.03, 95% CI: 0.56-1.90, P = 0.91; A1A1 vs A2A2: OR: 1.17, 95% CI: 0.64-2.13, P = 0.61; A1A2 vs A2A2: OR: 1.14, 95% CI: 0.79-1.65, P = 0.48; Figure 3 ).
In the meta-analysis of Taq1B (rs17294542), the studies of Xing et al 9 Figure 4 ). For Ser311Cys (rs1801028), the meta-analysis included 806 patients in two studies. 8, 12 The SerSer group had a significantly lower improvement in the PANSS total score than the SerCys group (WMD: −11.58, 95% CI: −17.35 to −5.18, P < 0.0001) and in the PANSS negative score (WMD: −13.53, 95% CI: −16.53 to −10.53, P < 0.0001; Figure 5 ). F I G U R E 6 Association between T939C genotypes and improvement in PANSS total score (%) and response to risperidone.
A, PANSS total score; B, Events: number of responders total score at baseline as the cut-off of response, no correlation was found between the polymorphism of −141C Ins/ Del and the response to risperidone therapy. Two articles 8, 9 explored the association of polymorphisms of T939C (rs6275) with effects of risperidone treatment in Chinese population. Han et al 8 found that T939C
was markedly associated with an improvement in PANSS total scores (P < 0.001). However, in Xing et al's 9 study, no significant differences in T939C allele frequencies between the responder and the nonresponder groups were observed. We calculated the WMDs and ORs of different genotype groups from the reported data in these two studies and presented the results in Figure 6A ,B.
Other SNPs were investigated. Han et al 8 reported that rs6277 C>T (CC vs TT) was correlated with a lower improvement to risperidone (P < 0.001). In the study by Kaur et al, 11 significant differences in the frequencies of TaqID (rs1800498) were found among the responder, partial responder, and nonresponder groups (P = 0.01). No significant association was found between rs1076562 and the response to risperidone treatment by Xing et al. polymorphism on effects of risperidone treatment in a Taiwanese population. Those with either SerSer or SerGly genotypes had better performance in negative symptoms after controlling for other prognostic factors than those with the GlyGly genotype (P = 0.0002 and 0.0092, respectively). However, no significant effect on PANSS total score was found. Xuan et al 17 enrolled 130 schizophrenic patients from mainland China to evaluate the association of DRD3 (Ser9Gly, rs324028, rs717668, rs3773678, and rs2134655) with BPRS over 8 weeks. No significant differences in allele or genotype distribution were found between the responder and nonresponder groups for any of the five polymorphisms (P > 0.1). In a study by Han et al 8 
of 690
Chinese patients, the improvement in the PANSS total score for the TT, TC, and CC genotypes were 20.99 ± 14.04, 22.79 ± 13.57 and 24.54 ± 14.78, respectively; however, these values were not significant (P = 0.101). Kim et al 18 used CGI-I <4 to categorize nonresponders in Korean patients. No significant association between Ser9Gly and response was found. Fijal et al 14 selected seven SNPs in DRD3 to test their association with the efficacy of risperidone in African American and white patients; they found that rs324028 was significant for the PANSS positive scores in the AfricanAmerican cohort (P = 0.006), whereas other SNPs (rs167770, rs2134655, rs324023, rs324026, rs324029, and Ser9Gly) were not associated with PANSS scores (P > 0.05).
| DISCUSSION
Risperidone is a widely prescribed antipsychotic for the treatment of schizophrenia, with a relatively high rate of ineffectiveness and intolerable side effects. 23 It is an atypical antipsychotic that displays stronger affinity for dopamine receptors than clozapine and olanzapine. Several observational studies suggested that the genetic composition of the dopamine receptors might be associated with the treatment effect or adverse reactions of risperidone.
Although there are some published reviews of the correlations between dopamine receptor genes and treatment efficacy of risperidone, they have not been updated in recent years. 24, 25 Furthermore, no systematic reviews or quantitative synthesis have been performed. Therefore, the two highlighted advantages in our study are: (a) systematic presentation of the currently published literature about the association between the gene polymorphisms of DRD1-3 and their effect on risperidone treatment, which included 24 SNPs; (b) quantitative results from meta-analyses for some SNPs of the dopamine receptor genes.
No correlation between SNPs of the DRD1 gene and risperidone efficacy has been previously reported. The study conducted by Hwang et al 26 indicated that the DRD1 rs686 polymorphism significantly impacted the patient's response to clozapine, however, its relationship with risperidone has not been explored. We noticed that for rs11746641 T>G in Han et al's 8 study, the difference between the three groups (GG, GA, and AA) did not reach a statistically significant level (P > 0.05) using Bonferroni correction analysis according to the authors; however, in comparison with the TT group, we found that the GG group exhibited a slight improvement in PANSS total score, as presented in Figure 2D . Further studies are needed to verify the effect of rs11746641. Different polymorphisms in DRD2 have been associated with effects of risperidone treatment, which was in accordance with expectations as risperidone has a better capacity for combinations with the dopamine D2 receptor than others. Ser311Cys polymorphisms were associated with an improvement in PANSS total score and a negative score in Chinese patients with schizophrenia, and Cys carriers have been related to better outcome for negative symptoms. In addition, Fijal et al 14 indicated that Ser311Cys was associated with PANSS negative symptom and PANSS total scores in white patients (P = 0.018 and P = 0.012, respectively), but not in African Americans (P > 0.05). The correlation between A241G and the effect of risperidone may differ in ethnic groups. In Chinese and Japanese population, carriers of the A allele showed greater improvement than those with the G allele, whereas no such correlation was found in African Americans and whites. The meta-analysis revealed that neither TaqIA or TaqIB in DRD2 was associated with the response to risperidone. Yasui-Furukori et al 15 compared the difference between A1 carriers (A1A1 + A1A2) and A2A2 carriers through the percentage improvement of BPRS score in 60 Japanese patients, which also indicated no statistically significant differences. In Ikeda et al's 13 study of 120 firstepisode Japanese patients, A1A1 carriers experienced significantly greater improvement in total PANSS score than the other genotypes (P < 0.05). As Ikeda did not divide the patients into responder or nonresponder group, this study was not included in our meta-analysis. In addition, it has been reported that −141C Ins/Del, T939C, rs6277 C>T, and TaqID might be associated with therapy response of risperidone, but there is currently a lack of supporting evidence. Based on current research, DRD3 polymorphisms do not appear to be associated with the improvement in PANSS total score; however, the Ser9Gly polymorphism may influence the improvement of negative symptoms. Moreover, as for African-American patients, rs324028 may have a significant association with the positive PANSS improvement. However, as these positive findings have not been replicated, further studies are still needed.
Several pharmacogenetic studies have studied specific antipsychotics, whereas other studies have investigated the genetic factors determining the response to a particular drug class. Given the variation in pharmacological profiles, only studies reporting the data for risperidone monotherapy were included in our study, which minimized bias.
As the included studies used different scales, such as PANSS, BPRS, and CGI, to evaluate the treatment efficacy, presented the data in different ways (change of score, improvement rate, or number of responders), or used different statistical methods, meta-analyses were performed only when multiple studies were available to merge. To present the results of the included studies more intuitively, we also calculated some of the mean differences and odds ratios from the original data in cases in which only one study investigated the SNP. Nevertheless, our study had the following limitations: (a) as the number of published studies was limited and some outcome were inconsistent, only a small number of studies were included in the meta-analysis; (b) inevitably, publication bias existed in the meta-analysis of the included studies, as varying doses were given and patients may carry different genotypes of other genes that may influence risperidone treatment effect, such as 5-HT receptor genes; and (c) intergroup bias may arise from different studies, for example different cut-offs to define the response, different durations of risperidone treatment, and previous medical treatments.
In summary, the results of the present study demonstrated that numerous SNPs of DRD2 might play a critical role in the effect of risperidone treatment. However, DRD1 is not likely to significantly impact the response to risperidone, and DRD3 might be associated with the improvement of negative symptoms. Thus, future studies should be conducted to verify any potential impact of dopamine receptor genes.
CONFLICTS OF INTEREST
All authors report no conflicts of interest.
